632 related articles for article (PubMed ID: 7583048)
21. Inhibition of glomerular visceral epithelial cell endocytosis during nephrosis induced by puromycin aminonucleoside.
Schwartz MM; Sharon Z; Pauli BU; Lewis EJ
Lab Invest; 1984 Dec; 51(6):690-6. PubMed ID: 6389977
[TBL] [Abstract][Full Text] [Related]
22. Treatment with the xanthine oxidase inhibitor, allopurinol, improves nerve and vascular function in diabetic rats.
Inkster ME; Cotter MA; Cameron NE
Eur J Pharmacol; 2007 Apr; 561(1-3):63-71. PubMed ID: 17291486
[TBL] [Abstract][Full Text] [Related]
23. Ameliorative effects of dietary protein restriction in chronic aminonucleoside nephrosis.
Diamond JR; Karnovsky MJ
J Lab Clin Med; 1987 May; 109(5):538-44. PubMed ID: 3572200
[TBL] [Abstract][Full Text] [Related]
24. Temocapril, a long-acting non-SH group angiotensin converting enzyme inhibitor, modulates glomerular injury in chronic puromycin aminonucleoside nephrosis.
Zheng Y; Shirato I; Maeda A; Kobayashi N; Liao J; Shou I; Fukui M; Tomino Y
J Nephrol; 2002; 15(1):36-41. PubMed ID: 11936424
[TBL] [Abstract][Full Text] [Related]
25. Unilateral renal disease in the rat. I. Clinical, morphologic, and glomerular mesangial functional features of the experimental model produced by renal perfusion with aminonucleoside.
Hoyer JR; Mauer SM; Michael AF
J Lab Clin Med; 1975 May; 85(5):756-68. PubMed ID: 1091713
[TBL] [Abstract][Full Text] [Related]
26. A scanning and transmission electron microscopic comparison of puromycin aminonucleoside-induced nephrosis to hyperalbuminemia-induced proteinuria with emphasis on kidney podocyte pedicel loss.
Andrews PM
Lab Invest; 1977 Feb; 36(2):183-97. PubMed ID: 839733
[TBL] [Abstract][Full Text] [Related]
27. Effects of aminonucleoside, daunomycin, and adriamycin on carbon oxidation by glomeruli.
Kaplan BS; Renaud L; Drummond KN
Lab Invest; 1976 Feb; 34(2):174-8. PubMed ID: 1249918
[TBL] [Abstract][Full Text] [Related]
28. Alterations in the glomerulus in aminonucleoside nephrosis in analbuminemic rats.
Abe H; Shibuya T; Odashima S; Arichi S; Nagase S
Nephron; 1988; 50(4):351-5. PubMed ID: 3237275
[TBL] [Abstract][Full Text] [Related]
29. Podocytic cytoskeletal disaggregation and basement-membrane detachment in puromycin aminonucleoside nephrosis.
Whiteside CI; Cameron R; Munk S; Levy J
Am J Pathol; 1993 May; 142(5):1641-53. PubMed ID: 8494056
[TBL] [Abstract][Full Text] [Related]
30. Effect of captopril on chronic puromycin aminonucleoside nephrosis in rats.
Radin MJ; Wilke WL; Fettman MJ
Res Commun Chem Pathol Pharmacol; 1986 Nov; 54(2):279-82. PubMed ID: 3538253
[TBL] [Abstract][Full Text] [Related]
31. The role of xanthine oxidase and xanthine dehydrogenase in skin ischemia.
Rees R; Smith D; Li TD; Cashmer B; Garner W; Punch J; Smith DJ
J Surg Res; 1994 Feb; 56(2):162-7. PubMed ID: 8121173
[TBL] [Abstract][Full Text] [Related]
32. [Effects of human Cu, Zn-superoxide dismutase in aminonucleoside nephrosis--evaluation of the morphology and glomerular basement membrane anionic charge sites].
Higuchi A
Nihon Jinzo Gakkai Shi; 1990 Jul; 32(7):767-75. PubMed ID: 2273594
[TBL] [Abstract][Full Text] [Related]
33. Effect of a low-protein diet on expression of non-muscle type myosin heavy-chain isoforms in glomeruli of rats with puromycin aminonucleoside nephrosis.
Koide H; Nakamura T; Kimura K; Ebihara I; Nagai R; Tomino Y
Nephrol Dial Transplant; 1996 Sep; 11(9):1769-74. PubMed ID: 8918620
[TBL] [Abstract][Full Text] [Related]
34. Further evidence for the role of free radicals in the limb teratogenicity of L-NAME.
Fantel AG; Person RE
Teratology; 2002 Jul; 66(1):24-32. PubMed ID: 12115777
[TBL] [Abstract][Full Text] [Related]
35. Sialic acid supplementation ameliorates puromycin aminonucleoside nephrosis in rats.
Pawluczyk IZ; Najafabadi MG; Brown JR; Bevington A; Topham PS
Lab Invest; 2015 Sep; 95(9):1019-28. PubMed ID: 26121320
[TBL] [Abstract][Full Text] [Related]
36. Key molecular events in puromycin aminonucleoside nephrosis rats.
Guan N; Ding J; Deng J; Zhang J; Yang J
Pathol Int; 2004 Sep; 54(9):703-11. PubMed ID: 15363039
[TBL] [Abstract][Full Text] [Related]
37. Renoprotective effect of topiroxostat via antioxidant activity in puromycin aminonucleoside nephrosis rats.
Kawamorita Y; Shiraishi T; Tamura Y; Kumagai T; Shibata S; Fujigaki Y; Hosoyamada M; Nakagawa T; Uchida S
Physiol Rep; 2017 Aug; 5(15):. PubMed ID: 28774949
[TBL] [Abstract][Full Text] [Related]
38. Time course of lipid peroxidation in puromycin aminonucleoside-induced nephropathy.
Fawcett JP; Jiang R; Walker RJ
Res Commun Mol Pathol Pharmacol; 1994 Nov; 86(2):227-34. PubMed ID: 7881871
[TBL] [Abstract][Full Text] [Related]
39. The impact of hepatic xanthine oxidase and xanthine dehydrogenase activities on liver function in chronic cholestasis.
Schimpl G; Pesendorfer P; Kuesz AM; Ratschek M; Höllwarth ME
Pediatr Surg Int; 2000; 16(4):297-301. PubMed ID: 10898233
[TBL] [Abstract][Full Text] [Related]
40. Incorporation of 35sulfate into the glomerular basement membrane in puromycin aminonucleoside nephrosis.
Garin EH; Boggs KP; Burke FC
Int J Pediatr Nephrol; 1985; 6(2):117-20. PubMed ID: 4030221
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
